Series Code,Series Name,Indicator Reference Number,Reference Area Code (M49),Reference Area Type [for UNSD use only],Reference Area Name,Time Period,Observation Value,Unit of Measurement,Nature of Data,Disaggregation classification,Time Detail,Reporting Type,Footnotes,Source Detail
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,1,1.0-Global,World,2019,24.9,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,53,2.1-Regional (SDG),Australia and New Zealand (M49),2019,18.5,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,143,2.1-Regional (SDG),Central Asia (M49),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,62,2.1-Regional (SDG),Central Asia (M49) and Southern Asia (MDG=M49),2019,55.99,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,30,2.1-Regional (SDG),Eastern Asia (M49),2019,42.51,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,753,2.1-Regional (SDG),Eastern Asia (M49) and South-eastern Asia (MDG=M49),2019,32.53,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,150,2.1-Regional (SDG),Europe (M49),2019,10.47,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,419,2.1-Regional (SDG),Latin America and the Caribbean (MDG=M49),2019,31.29,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,15,2.1-Regional (SDG),Northern Africa (M49),2019,32.91,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,21,2.1-Regional (SDG),Northern America (M49),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,513,2.1-Regional (SDG),Northern America (M49) and Europe (M49),2019,10.47,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,9,2.1-Regional (SDG),Oceania (M49),2019,18.47,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,543,2.1-Regional (SDG),Oceania (M49) excluding Australia and New Zealand (M49),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,35,2.1-Regional (SDG),South-eastern Asia (MDG=M49),2019,24.09,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,34,2.1-Regional (SDG),Southern Asia (MDG=M49),2019,55.99,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,202,2.1-Regional (SDG),Sub-Saharan Africa (M49),2019,10.34,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,145,2.1-Regional (SDG),Western Asia (M49),2019,40,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,747,2.1-Regional (SDG),Western Asia (M49) and Northern Africa (M49),2019,40,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,432,2.3-Other groupings,Landlocked developing countries (LLDCs),2019,6.06,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,199,2.3-Other groupings,Least Developed Countries (LDCs),2019,15.56,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,722,2.3-Other groupings,Small Island Developing States (SIDS),2019,28.65,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,2,2.4-Regional (M49),Africa,2019,17.44,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,142,2.4-Regional (M49),Asia,2019,39.46,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,19,2.4-Regional (M49),Americas,2019,31.29,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,29,2.4-Regional (M49),Caribbean (M49),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,13,2.4-Regional (M49),Central America (M49),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,14,2.4-Regional (M49),Eastern Africa (M49),2019,10.34,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,151,2.4-Regional (M49),Eastern Europe (M49),2019,14.94,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,54,2.4-Regional (M49),Melanesia (M49),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,57,2.4-Regional (M49),Micronesia (M49),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,17,2.4-Regional (M49),Middle Africa (M49),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,154,2.4-Regional (M49),Northern Europe (M49),2019,7.88,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,61,2.4-Regional (M49),Polynesia (M49),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,5,2.4-Regional (M49),South America (M49),2019,31.29,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,18,2.4-Regional (M49),Southern Africa (M49),2019,21.35,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,39,2.4-Regional (M49),Southern Europe (M49),2019,31.08,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,11,2.4-Regional (M49),Western Africa (M49),2019,2.5,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,155,2.4-Regional (M49),Western Europe (M49),2019,5.74,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,746,2.5-Regional (MDG),Northern Africa (MDG),2019,17.44,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,738,2.5-Regional (MDG),Sub-Saharan Africa (MDG),2019,15.85,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,518,2.5-Regional (MDG),Eastern Asia (MDG),2019,48.61,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,223,2.5-Regional (MDG),    Eastern Asia excluding China (MDG),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,127,2.5-Regional (MDG),    Southern Asia excluding India (MDG),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,485,2.5-Regional (MDG),Western Asia (MDG),2019,40,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,135,2.5-Regional (MDG),Caucasus and Central Asia (MDG),2019,14.29,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,515,2.5-Regional (MDG),Developing regions (MDG),2019,33.8,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,514,2.5-Regional (MDG),Developed regions (MDG),2019,12.52,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,WHO-GLASS
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,4,3.0-Country,Afghanistan,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,248,3.0-Country,Åland Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,8,3.0-Country,Albania,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,12,3.0-Country,Algeria,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,16,3.0-Country,American Samoa,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,20,3.0-Country,Andorra,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,24,3.0-Country,Angola,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,660,3.0-Country,Anguilla,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,28,3.0-Country,Antigua and Barbuda,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,32,3.0-Country,Argentina,2019,42.03,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,51,3.0-Country,Armenia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,533,3.0-Country,Aruba,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,36,3.0-Country,Australia,2019,18.47,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,40,3.0-Country,Austria,2019,5.26,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,31,3.0-Country,Azerbaijan,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,44,3.0-Country,Bahamas,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,48,3.0-Country,Bahrain,2019,40,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,50,3.0-Country,Bangladesh,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,52,3.0-Country,Barbados,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,112,3.0-Country,Belarus,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,56,3.0-Country,Belgium,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,84,3.0-Country,Belize,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,204,3.0-Country,Benin,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,60,3.0-Country,Bermuda,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,64,3.0-Country,Bhutan,2019,20.79,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,68,3.0-Country,Bolivia (Plurinational State of),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,535,3.0-Country,"Bonaire, Sint Eustatius and Saba",2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,70,3.0-Country,Bosnia and Herzegovina,2019,10.55,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,72,3.0-Country,Botswana,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,76,3.0-Country,Brazil,2019,20.56,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,86,3.0-Country,British Indian Ocean Territory,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,92,3.0-Country,British Virgin Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,96,3.0-Country,Brunei Darussalam,2019,12.3,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,100,3.0-Country,Bulgaria,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,854,3.0-Country,Burkina Faso,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,108,3.0-Country,Burundi,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,132,3.0-Country,Cabo Verde,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,116,3.0-Country,Cambodia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,120,3.0-Country,Cameroon,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,124,3.0-Country,Canada,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,136,3.0-Country,Cayman Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,140,3.0-Country,Central African Republic,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,148,3.0-Country,Chad,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,830,3.0-Country,Channel Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,152,3.0-Country,Chile,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,156,3.0-Country,China,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,344,3.0-Country,"China, Hong Kong Special Administrative Region",2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,446,3.0-Country,"China, Macao Special Administrative Region",2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,162,3.0-Country,Christmas Island,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,166,3.0-Country,Cocos (Keeling) Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,170,3.0-Country,Colombia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,174,3.0-Country,Comoros,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,178,3.0-Country,Congo,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,184,3.0-Country,Cook Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,188,3.0-Country,Costa Rica,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,384,3.0-Country,Côte d'Ivoire,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,191,3.0-Country,Croatia,2019,24.86,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,192,3.0-Country,Cuba,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,531,3.0-Country,Curaçao,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,196,3.0-Country,Cyprus,2019,100,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,203,3.0-Country,Czechia,2019,12.52,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,408,3.0-Country,Democratic People's Republic of Korea,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,180,3.0-Country,Democratic Republic of the Congo,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,208,3.0-Country,Denmark,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,262,3.0-Country,Djibouti,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,212,3.0-Country,Dominica,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,214,3.0-Country,Dominican Republic,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,218,3.0-Country,Ecuador,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,818,3.0-Country,Egypt,2019,79.59,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,222,3.0-Country,El Salvador,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,226,3.0-Country,Equatorial Guinea,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,232,3.0-Country,Eritrea,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,233,3.0-Country,Estonia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,231,3.0-Country,Ethiopia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,238,3.0-Country,Falkland Islands (Malvinas),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,234,3.0-Country,Faroe Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,242,3.0-Country,Fiji,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,246,3.0-Country,Finland,2019,2.07,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,250,3.0-Country,France,2019,12.52,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,254,3.0-Country,French Guiana,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,258,3.0-Country,French Polynesia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,260,3.0-Country,French Southern and Antarctic Territories,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,266,3.0-Country,Gabon,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,270,3.0-Country,Gambia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,268,3.0-Country,Georgia,2019,12.52,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,276,3.0-Country,Germany,2019,6.8,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,288,3.0-Country,Ghana,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,292,3.0-Country,Gibraltar,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,300,3.0-Country,Greece,2019,43.41,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,304,3.0-Country,Greenland,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,308,3.0-Country,Grenada,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,312,3.0-Country,Guadeloupe,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,316,3.0-Country,Guam,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,320,3.0-Country,Guatemala,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,831,3.0-Country,Guernsey,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,324,3.0-Country,Guinea,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,624,3.0-Country,Guinea-Bissau,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,328,3.0-Country,Guyana,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,332,3.0-Country,Haiti,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,334,3.0-Country,Heard Island and McDonald Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,336,3.0-Country,Holy See,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,340,3.0-Country,Honduras,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,348,3.0-Country,Hungary,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,352,3.0-Country,Iceland,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,356,3.0-Country,India,2019,60.61,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,360,3.0-Country,Indonesia,2019,39.85,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,364,3.0-Country,Iran (Islamic Republic of),2019,39.08,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,368,3.0-Country,Iraq,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,372,3.0-Country,Ireland,2019,14.96,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,833,3.0-Country,Isle of Man,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,376,3.0-Country,Israel,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,380,3.0-Country,Italy,2019,38.75,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,388,3.0-Country,Jamaica,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,392,3.0-Country,Japan,2019,36.42,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,832,3.0-Country,Jersey,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,400,3.0-Country,Jordan,2019,72.39,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,398,3.0-Country,Kazakhstan,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,404,3.0-Country,Kenya,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,296,3.0-Country,Kiribati,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,414,3.0-Country,Kuwait,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,417,3.0-Country,Kyrgyzstan,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,418,3.0-Country,Lao People's Democratic Republic,2019,6.06,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,428,3.0-Country,Latvia,2019,12.28,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,422,3.0-Country,Lebanon,2019,25,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,426,3.0-Country,Lesotho,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,430,3.0-Country,Liberia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,434,3.0-Country,Libya,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,438,3.0-Country,Liechtenstein,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,440,3.0-Country,Lithuania,2019,9.3,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,442,3.0-Country,Luxembourg,2019,6.22,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,450,3.0-Country,Madagascar,2019,33.33,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,454,3.0-Country,Malawi,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,458,3.0-Country,Malaysia,2019,19.53,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,462,3.0-Country,Maldives,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,466,3.0-Country,Mali,2019,2.5,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,470,3.0-Country,Malta,2019,22.08,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,584,3.0-Country,Marshall Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,474,3.0-Country,Martinique,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,478,3.0-Country,Mauritania,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,480,3.0-Country,Mauritius,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,175,3.0-Country,Mayotte,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,484,3.0-Country,Mexico,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,583,3.0-Country,Micronesia (Federated States of),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,492,3.0-Country,Monaco,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,496,3.0-Country,Mongolia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,499,3.0-Country,Montenegro,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,500,3.0-Country,Montserrat,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,504,3.0-Country,Morocco,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,508,3.0-Country,Mozambique,2019,10.34,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,104,3.0-Country,Myanmar,2019,55.61,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,516,3.0-Country,Namibia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,520,3.0-Country,Nauru,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,524,3.0-Country,Nepal,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,528,3.0-Country,Netherlands,2019,1.65,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,540,3.0-Country,New Caledonia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,554,3.0-Country,New Zealand,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,558,3.0-Country,Nicaragua,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,562,3.0-Country,Niger,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,566,3.0-Country,Nigeria,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,570,3.0-Country,Niue,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,574,3.0-Country,Norfolk Island,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,580,3.0-Country,Northern Mariana Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,578,3.0-Country,Norway,2019,1.27,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,512,3.0-Country,Oman,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,586,3.0-Country,Pakistan,2019,64.98,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,585,3.0-Country,Palau,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,591,3.0-Country,Panama,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,598,3.0-Country,Papua New Guinea,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,600,3.0-Country,Paraguay,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,604,3.0-Country,Peru,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,608,3.0-Country,Philippines,2019,50.88,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,612,3.0-Country,Pitcairn,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,616,3.0-Country,Poland,2019,14.94,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,620,3.0-Country,Portugal,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,630,3.0-Country,Puerto Rico,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,634,3.0-Country,Qatar,2019,33.8,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,410,3.0-Country,Republic of Korea,2019,48.61,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,498,3.0-Country,Republic of Moldova,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,638,3.0-Country,Réunion,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,642,3.0-Country,Romania,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,643,3.0-Country,Russian Federation,2019,26.67,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,646,3.0-Country,Rwanda,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,652,3.0-Country,Saint Barthélemy,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,654,3.0-Country,Saint Helena,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,659,3.0-Country,Saint Kitts and Nevis,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,662,3.0-Country,Saint Lucia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,663,3.0-Country,Saint Martin (French Part),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,666,3.0-Country,Saint Pierre and Miquelon,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,670,3.0-Country,Saint Vincent and the Grenadines,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,882,3.0-Country,Samoa,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,674,3.0-Country,San Marino,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,678,3.0-Country,Sao Tome and Principe,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,682,3.0-Country,Saudi Arabia,2019,48.94,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,686,3.0-Country,Senegal,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,688,3.0-Country,Serbia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,690,3.0-Country,Seychelles,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,694,3.0-Country,Sierra Leone,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,702,3.0-Country,Singapore,2019,28.65,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,534,3.0-Country,Sint Maarten (Dutch part),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,703,3.0-Country,Slovakia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,705,3.0-Country,Slovenia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,90,3.0-Country,Solomon Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,706,3.0-Country,Somalia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,710,3.0-Country,South Africa,2019,21.35,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,239,3.0-Country,South Georgia and the South Sandwich Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,728,3.0-Country,South Sudan,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,724,3.0-Country,Spain,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,144,3.0-Country,Sri Lanka,2019,55.99,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,275,3.0-Country,State of Palestine,2019,81.78,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,729,3.0-Country,Sudan,2019,48.39,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,740,3.0-Country,Suriname,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,744,3.0-Country,Svalbard and Jan Mayen Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,748,3.0-Country,Swaziland,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,752,3.0-Country,Sweden,2019,1.8,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,756,3.0-Country,Switzerland,2019,3.91,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,760,3.0-Country,Syrian Arab Republic,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,762,3.0-Country,Tajikistan,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,764,3.0-Country,Thailand,2019,12.43,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,807,3.0-Country,The former Yugoslav Republic of Macedonia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,626,3.0-Country,Timor-Leste,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,768,3.0-Country,Togo,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,772,3.0-Country,Tokelau,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,776,3.0-Country,Tonga,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,780,3.0-Country,Trinidad and Tobago,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,788,3.0-Country,Tunisia,2019,17.44,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,792,3.0-Country,Turkey,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,795,3.0-Country,Turkmenistan,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,796,3.0-Country,Turks and Caicos Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,798,3.0-Country,Tuvalu,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,800,3.0-Country,Uganda,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,804,3.0-Country,Ukraine,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,784,3.0-Country,United Arab Emirates,2019,36.23,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,826,3.0-Country,United Kingdom of Great Britain and Northern Ireland,2019,10.4,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,834,3.0-Country,United Republic of Tanzania,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,581,3.0-Country,United States minor outlying islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,840,3.0-Country,United States of America,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,850,3.0-Country,United States Virgin Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,858,3.0-Country,Uruguay,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,860,3.0-Country,Uzbekistan,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,548,3.0-Country,Vanuatu,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,862,3.0-Country,Venezuela (Bolivarian Republic of),2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,704,3.0-Country,Viet Nam,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,876,3.0-Country,Wallis and Futuna Islands,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,732,3.0-Country,Western Sahara,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,887,3.0-Country,Yemen,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,894,3.0-Country,Zambia,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
,Percentage of bloodstream infections due to selected antimicrobial-resistant organisms,3.d.2,716,3.0-Country,Zimbabwe,2019,,Percentage,CA,Not applicable,Q1 2019 - Q4 2019,G,Percentage of bloodstream infection due to methicillin-resistant Staphylococcus aureus (MRSA) among patients seeking care and whose blood sample is taken and tested.,AMR Surveillance National Coordinating Center 
